Chemotherapy for Colon Adenocarcinoma
For stage III colon adenocarcinoma, use FOLFOX (5-FU/leucovorin/oxaliplatin) or CAPOX (capecitabine/oxaliplatin) as standard adjuvant therapy, with treatment duration of 3 months for low-risk disease (T1-3, N1) or 6 months for high-risk disease (T4 or N2). For stage II disease, adjuvant chemotherapy should only be offered to patients with high-risk features, and for metastatic disease, fluoropyrimidine-platinum combinations remain first-line treatment.
Stage III Disease (Node-Positive)
Adjuvant chemotherapy is mandatory for all stage III colon cancer 1. The addition of oxaliplatin to fluoropyrimidine-based therapy significantly improves both disease-free survival and overall survival compared to fluoropyrimidine alone 1, 2.
Preferred Regimens:
mFOLFOX6: Oxaliplatin 85 mg/m² IV day 1, leucovorin 400 mg/m² IV day 1,5-FU 400 mg/m² IV bolus day 1, then 5-FU 1200 mg/m²/day × 2 days continuous infusion, repeated every 2 weeks 3
CAPOX (CapeOx): Oxaliplatin 130 mg/m² IV day 1, capecitabine 1000 mg/m² PO twice daily days 1-14, repeated every 3 weeks 3
Treatment Duration Based on Risk Stratification:
The IDEA collaboration established risk-adapted duration 4:
- Low-risk (T1-3, N1): 3 months of CAPOX is non-inferior to 6 months, with significantly less neurotoxicity (3% vs 9% grade ≥3) 4
- High-risk (T4 or N2): 6 months of either FOLFOX or CAPOX is recommended 4
Important caveat: FOLFOX showed better outcomes than CAPOX in high-risk patients in the IDEA analysis, making it the preferred choice for T4 or N2 disease 4.
Alternative Single-Agent Options:
If oxaliplatin is contraindicated or declined:
- Capecitabine: 1250 mg/m² PO twice daily days 1-14 every 3 weeks for 24 weeks 3
- Infusional 5-FU/LV regimens 1
Stage II Disease (Node-Negative)
Adjuvant chemotherapy is NOT routinely recommended for standard-risk stage II colon cancer 5, 6. The absolute benefit is small (approximately 3-5% improvement in 5-year survival) 7.
High-Risk Features Warranting Consideration of Adjuvant Therapy:
Offer adjuvant chemotherapy when these features are present 1, 5:
- T4 tumors (definite indication) 5
- Poorly differentiated or undifferentiated histology
- Lymphovascular invasion
- Perineural invasion
- Bowel obstruction or perforation at presentation
- <12 lymph nodes examined in surgical specimen
- Elevated preoperative CEA
- Grade BD3 tumor budding 5
Critical Exception - MSI Status:
Patients with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) tumors should NOT receive fluoropyrimidine monotherapy 7, 2. Evidence suggests potential harm from 5-FU-based chemotherapy in stage II MSI-H tumors 7. If chemotherapy is deemed necessary for dMMR/MSI-H patients with multiple high-risk features, use oxaliplatin-containing regimens 5.
Recommended Regimens for High-Risk Stage II:
- Preferred: Fluoropyrimidine monotherapy (capecitabine or 5-FU/LV) 8, 6
- Alternative: FOLFOX or CAPOX may be considered, though evidence of benefit over monotherapy is limited 5
Metastatic/Unresectable Disease
While the provided evidence focuses primarily on adjuvant therapy, guidelines indicate that fluoropyrimidine-platinum combinations (FOLFOX or CAPOX) serve as first-line treatment for metastatic colon cancer 1. The evidence supports these regimens showing superior response rates compared to fluoropyrimidine alone in the metastatic setting.
Regimens to AVOID:
Do not use these in the adjuvant setting 3:
- Irinotecan-containing regimens (IFL, FOLFIRI): No survival benefit and increased toxicity 3
- Bevacizumab: No DFS benefit, possible harm 3
- Cetuximab: No benefit in wild-type KRAS, worse outcomes in mutant KRAS 3
- FLOX regimen: Excessive diarrhea (38% grade 3/4) compared to FOLFOX (10.8%) 3, 2
Key Clinical Pitfalls:
Neurotoxicity management: Grade ≥3 neurotoxicity occurs in 16% with 6 months FOLFOX vs 3% with 3 months 4. Consider dose reduction or early discontinuation of oxaliplatin while continuing fluoropyrimidine.
DPD deficiency screening: Strongly recommended before initiating fluoropyrimidine therapy to prevent severe toxicity 2.
Timing: Initiate adjuvant therapy within 6-8 weeks post-surgery once patient has recovered 7.
MSI testing: Mandatory for all stage II patients to guide treatment decisions 2, 5.